MetaCap

NuCana (NCNA) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NuCana is the larger company by market cap ($3.6 million vs $3.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NCNA-34.25%XTLB-30.81%
+4%-17%-39%
Oct 7, 20261 yearNov 20, 2026
NCNA-31.86%XTLB-30.81%
+4%-15%-34%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NCNA versus XTLB key metrics
MetricNCNAXTLB
Share price$0.7495$1.37
Market cap$3.61M$3.37M
1-day change+4.39%-5.84%
EPS (TTM)$0.00$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$451.00K
Net income (latest FY)—$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$4.55$5.64
52-week low$0.62$1.37
Distance from 52-week high-83.53%-75.71%
Average volume118.13K6.58K
Shares outstanding4.82M2.46M
Employees104
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NuCana

NCNA stock →

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

NCNA vs XTLB FAQ

Which is bigger, NuCana or XTL Biopharmaceuticals?

NuCana (NCNA) is larger, with a market capitalization of $3.61M compared with $3.37M for XTL Biopharmaceuticals (XTLB).

Are NuCana and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons